CN114887666A - Catalyst and application thereof - Google Patents

Catalyst and application thereof Download PDF

Info

Publication number
CN114887666A
CN114887666A CN202210501832.6A CN202210501832A CN114887666A CN 114887666 A CN114887666 A CN 114887666A CN 202210501832 A CN202210501832 A CN 202210501832A CN 114887666 A CN114887666 A CN 114887666A
Authority
CN
China
Prior art keywords
flurbiprofen
phosphine ligand
catalyst
fluorobiphenyl
nickel salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202210501832.6A
Other languages
Chinese (zh)
Other versions
CN114887666B (en
Inventor
唐波
杨朋
孙雅鑫
杨光
张力
马瑜
付凯悦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Normal University
Original Assignee
Shandong Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Normal University filed Critical Shandong Normal University
Priority to CN202210501832.6A priority Critical patent/CN114887666B/en
Publication of CN114887666A publication Critical patent/CN114887666A/en
Application granted granted Critical
Publication of CN114887666B publication Critical patent/CN114887666B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2409—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00—Asymmetric syntheses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/26—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton
    • C07C17/263—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/84—Metals of the iron group
    • B01J2531/847—Nickel
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to the technical field of drug synthesis, in particular to a preparation method of flurbiprofen, which comprises the following steps: 4-bromo-2-fluorobiphenyl and trimethylsilyl acetylene are subjected to Sonogashira coupling reaction under the catalysis of palladium to obtain 4-trimethylsilyl ethynyl-2-fluorobiphenyl, and the product is subjected to removal of trimethylsilyl in an alkaline solution without separation to obtain 4-ethynyl-2-fluorobiphenyl; and then taking a complex formed in situ by nickel and phosphine ligands as a catalyst, taking formic acid as a carboxylation and hydrogenation reagent, carrying out hydrocarboxylation-hydrogenation tandem reaction on the 4-ethynyl-2-fluorobiphenyl, and purifying to obtain the flurbiprofen. The raw material source is easy to obtain, the route is short, the operation is simple and convenient, the reaction condition is mild, and the yield is high; the ethynyl is directly converted into the propionic acid group through an efficient one-pot tandem reaction, and the racemic flurbiprofen, the levorotatory flurbiprofen and the dextrorotatory flurbiprofen can be synthesized only by changing the types of phosphine ligands, so that the racemic flurbiprofen is prevented from being prepared into the optically pure flurbiprofen through fussy and inefficient resolution.

Description

Catalyst and application thereof
The invention is a divisional application, and the original application number is as follows: 202110104844.0, filing date: to 2021.01.26, the invention creates the name: a method for preparing flurbiprofen.
Technical Field
The invention relates to the technical field of drug synthesis, in particular to a preparation method of flurbiprofen, which is used for preparing racemic flurbiprofen, optically pure levorotatory flurbiprofen and dextrorotatory flurbiprofen.
Background
The information in this background section is only for enhancement of understanding of the general background of the invention and is not necessarily to be construed as an admission or any form of suggestion that this information forms the prior art that is already known to a person of ordinary skill in the art.
The chemical name of Flurbiprofen (Flurbiprofen) is 2- (2-fluoro-4-biphenyl) -propionic acid, and the chemical structure is shown as (1). Is a powerful non-steroidal anti-inflammatory analgesic developed by British Blakez company. The anti-inflammatory and analgesic effects of the aspirin sustained-release tablet are respectively 250 times and 50 times of those of aspirin, the aspirin sustained-release tablet is stronger than ibuprofen, and the ibuprofen sustained-release tablet is lower in toxicity and is the most powerful one of the currently known propionic acid non-steroidal anti-inflammatory drugs. It is used for treating rheumatic arthritis, rheumatoid arthritis, ankylosing spondylitis, degenerative arthritis, eye inflammation, etc., and can also be used for relieving traumatic pain, postoperative pain and various cancer pain. From the chemical structure, flurbiprofen contains one chiral carbon atom, and thus has a pair of enantiomers (2) and (3). Although the racemes are used in the prior medicine, the research shows that the two isomers have different physiological activities, the anti-inflammatory and analgesic activities of the flurbiprofen are mainly generated by the dextroisomer (S) - (+) -flurbiprofen (2), and the levoisomer (R) - (-) -flurbiprofen (3) has anticancer activity and can be also used for treating senile dementia. Therefore, the synthesis of optically pure levorotatory flurbiprofen and dextrorotatory flurbiprofen is of great significance, and can reduce the dosage, reduce side effects, treat different types of diseases and the like.
Figure BDA0003635708750000011
At present, various methods for synthesizing racemic flurbiprofen have been reported at home and abroad, wherein the various methods have the problems of long reaction route, difficult raw material source, complex operation, harsh conditions and the like. There are also many routes which involve the intermediate of 4-bromo-2-fluorobiphenyl or directly as starting material, where 4-bromo-2-fluorobiphenyl is prepared as grignard reagent, coupled with 2-halopropionate, sodium 2-halopropionate or 2-cyanopropionate, and hydrolyzed or acidified to obtain flurbiprofen. Although the reaction is simple, strict anhydrous conditions are required for preparing the grignard reagent, and the reaction needs to be monitored closely to prevent safety problems such as material flushing and deflagration caused by sudden heat release. The research shows that 4-bromo-2-fluorobiphenyl is converted into 4-vinyl-2-fluorobiphenyl through Grignard reaction, alpha-carboxylation is carried out under palladium catalysis and 30Bar carbon monoxide pressure to obtain flurbiprofen, noble metal and high-pressure CO are needed in the route, and the product contains beta-carboxylation products, so that the separation is difficult and the method is not suitable for large-scale production. In other researches, 4-bromo-2-fluorobiphenyl is converted into corresponding boric acid, the boric acid is coupled with 2-diazopropionate to obtain acrylic ester, and flurbiprofen is obtained through hydrogenation and hydrolysis.
The optically pure flurbiprofen is mainly obtained by resolution or asymmetric synthesis of racemate. Chemical resolving agents reported are, for example, dextran octylamine, isosorbide monobenzyl ether, (S) -phenylethylamine, (S) -3-methyl-2-phenylbutylamine, chiral beta-hydroxyamino acids, etc., which give only levo-or dextro-flurbiprofen of high optical purity, reported yields being calculated on the basis of half of the racemic material (the content of the isomer), generally between 60 and 80%, while the optical purity of the other isomer is not high or is discarded. The racemic flurbiprofen and the chiral resolution reagent are precious, and the chemical resolution method has complicated repeated recrystallization steps, so the production cost is high. Through the method of catalyzing biphenylmalonate decarboxylation or biphenylpropionic acid ethyl ester hydrolysis, although levorotatory flurbiprofen and dextrorotatory flurbiprofen can be obtained at the same time, the cost is very high, the steps are complicated, and the yield is low. The high performance liquid chromatography or the chiral ionic liquid resolution method also has the problems of expensive chiral column packing, limited resolution scale and the like. In the literature, chiral transition metal catalyst is used to perform asymmetric hydrogenation on biphenylyl acrylic acid to obtain dextro-flurbiprofen with high optical purity, wherein the biphenylyl acrylic acid can be obtained by converting 4-bromo-2-fluorobiphenyl into 4-acetylene-2-fluorobiphenyl through palladium-catalyzed coupling reaction and then performing palladium-catalyzed hydrocarboxylation reaction, or by coupling 4-bromo-2-fluorobiphenyl with pyruvate through Grignard reaction and then heating and dehydrating. The total synthesis route is still longer, the steps of separation and purification are more, and the noble metal catalyst is more used.
The inventors found that for the synthetic route of racemic and optically pure flurbiprofen, many pharmaceutical enterprises and colleges are continuously trying to develop more effective and concise synthetic routes due to the excellent anti-inflammatory analgesic and other potential efficacies of flurbiprofen; in the synthetic route in the prior art, only a racemate can be generally obtained, and then one of a left-handed rotation or a right-handed rotation is obtained through resolution; it still needs to design more reasonable starting materials, shortens the synthetic route and reduces the use of chiral noble metal catalysts.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a preparation method of flurbiprofen, which can synthesize racemic flurbiprofen, levo-flurbiprofen and dextro-flurbiprofen by selecting a suitable catalyst ligand from 4-bromo-2-fluorobiphenyl as a raw material, and has the advantages of short synthetic route, high yield, low consumption, health, safety, environmental protection and the like.
In order to achieve the above object, the technical solution of the present invention is as follows:
in the first aspect of the invention, a method for preparing flurbiprofen is provided, a Sonogashira coupling reaction is adopted, 4-bromo-2-fluorobiphenyl and trimethylsilyl acetylene are subjected to a coupling reaction under the catalysis of palladium to obtain 4-trimethylsilyl ethynyl-2-fluorobiphenyl, and the trimethylsilyl group is removed in an alkaline solution without separating a product to obtain 4-ethynyl-2-fluorobiphenyl; and then taking a complex formed in situ by nickel and phosphine ligands as a catalyst, taking formic acid as a carboxylation and hydrogenation reagent, carrying out hydrocarboxylation-hydrogenation tandem reaction on the 4-ethynyl-2-fluorobiphenyl, and purifying to obtain the flurbiprofen.
Specifically, the preparation method of flurbiprofen comprises the following steps:
step a: dissolving 4-bromo-2-fluorobiphenyl and trimethylsilyl acetylene in an organic solvent by adopting a Sonogashira coupling reaction, and reacting under stirring and heating in the presence of cuprous iodide and alkali by using a palladium catalyst; after the reaction is finished, the solvent is evaporated to dryness, and the product is directly subjected to the next reaction without separation;
step b: dissolving the mixture obtained in the step a in an organic solvent, and removing trimethylsilyl groups under the action of alkali to obtain 4-ethynyl-2-fluorobiphenyl;
step c: dissolving 4-ethynyl-2-fluorobiphenyl in an organic solvent, taking a complex generated in situ by divalent nickel salt and a phosphine ligand as a catalyst, heating and stirring for reaction under the action of acid anhydride, formic acid and triethylamine, and carrying out aftertreatment to obtain high-purity racemic flurbiprofen;
step d: dissolving 4-ethynyl-2-fluorobiphenyl in an organic solvent, heating and stirring for reaction under the action of acid anhydride, formic acid and triethylamine by taking a complex generated in situ by divalent nickel salt and an R-configuration chiral phosphine ligand as a catalyst, and carrying out aftertreatment to obtain high-purity levo-flurbiprofen;
step e: dissolving 4-ethynyl-2-fluorobiphenyl in an organic solvent, heating and stirring for reaction under the action of acid anhydride, formic acid and triethylamine by taking a complex generated in situ by a divalent nickel salt and an S-configuration chiral phosphine ligand as a catalyst, and carrying out post-treatment to obtain high-purity dextro-flurbiprofen;
wherein the order of steps c, d and e is not limited.
The specific embodiment of the invention has the following beneficial effects:
the specific embodiment of the invention provides a method for preparing flurbiprofen, which has the advantages of easily obtained raw material sources, short route, simple and convenient operation, mild reaction conditions and high yield; the ethynyl is directly converted into the propionic acid group through efficient one-pot tandem reaction, in the one-pot synthesis step, the racemic flurbiprofen, levorotatory flurbiprofen and dextrorotatory flurbiprofen can be synthesized only by changing the type of the phosphine ligand, and the preparation of the optically pure flurbiprofen from the racemic flurbiprofen through complicated and low-efficiency resolution is avoided.
Detailed Description
It should be noted that the following detailed description is exemplary and is intended to provide further explanation of the disclosure. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs.
It is noted that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of exemplary embodiments according to the present application. As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, and it should be understood that when the terms "comprises" and/or "comprising" are used in this specification, they specify the presence of stated features, steps, operations, devices, components, and/or combinations thereof, unless the context clearly indicates otherwise.
As discussed in the background of the invention section,
in one embodiment of the invention, a method for preparing flurbiprofen is provided, a Sonogashira coupling reaction is adopted, 4-bromo-2-fluorobiphenyl and trimethylsilylacetylene are subjected to a coupling reaction under the catalysis of palladium to obtain 4-trimethylsilylethynyl-2-fluorobiphenyl, and the product is subjected to removal of trimethylsilylethynyl in an alkaline solution without separation to obtain 4-ethynyl-2-fluorobiphenyl; and then taking a complex formed by the nickel and phosphine ligands in situ as a catalyst, taking formic acid as a carboxylation and hydrogenation reagent, carrying out hydrocarboxylation-hydrogenation tandem reaction on the 4-ethynyl-2-fluorobiphenyl, and purifying to obtain the flurbiprofen.
Specifically, the preparation method of flurbiprofen comprises the following steps:
step a: dissolving 4-bromo-2-fluorobiphenyl and trimethylsilyl acetylene in an organic solvent by adopting a Sonogashira coupling reaction, and reacting under stirring and heating in the presence of cuprous iodide and alkali by using a palladium catalyst; after the reaction is finished, the solvent is evaporated to dryness, and the product is directly subjected to the next reaction without separation;
step b: dissolving the mixture obtained in the step a in an organic solvent, and removing trimethylsilyl groups under the action of alkali to obtain 4-ethynyl-2-fluorobiphenyl;
step c: dissolving 4-ethynyl-2-fluorobiphenyl in an organic solvent, taking a complex generated in situ by divalent nickel salt and a phosphine ligand as a catalyst, heating and stirring for reaction under the action of acid anhydride, formic acid and triethylamine, and carrying out aftertreatment to obtain high-purity racemic flurbiprofen;
step d: dissolving 4-ethynyl-2-fluorobiphenyl in an organic solvent, heating and stirring for reaction under the action of acid anhydride, formic acid and triethylamine by taking a complex generated in situ by a divalent nickel salt and an R-configuration chiral phosphine ligand as a catalyst, and carrying out post-treatment to obtain high-purity levo-flurbiprofen;
step e: dissolving 4-ethynyl-2-fluorobiphenyl in an organic solvent, heating and stirring for reaction under the action of acid anhydride, formic acid and triethylamine by taking a complex generated in situ by a divalent nickel salt and an S-configuration chiral phosphine ligand as a catalyst, and carrying out post-treatment to obtain high-purity dextro-flurbiprofen;
wherein the order of steps c, d and e is not limited.
In a specific embodiment, the molar ratio of 4-bromo-2-fluorobiphenyl (4) to trimethylsilylacetylene (5) in step a is 1: (1.2-1.5), preferably 1: 1.25.
in a specific embodiment, the solvent in step a is one or a combination of several of tetrahydrofuran, acetonitrile, ethyl acetate and N, N-dimethylformamide, and tetrahydrofuran is preferred.
In a specific embodiment, the palladium catalyst in step a is Pd (PPh) 3 ) 2 Cl 2 、Pd(dppf) 2 Cl 2 、Pd(PPh 2 ) 4 Preferably Pd (PPh) 3 ) 2 Cl 2 。
In a particular embodiment, the molar ratio of the palladium catalyst to 4-bromo-2-fluorobiphenyl (4) in step a is 1: (20-100), preferably 1: 50.
in a particular embodiment, the molar ratio of cuprous iodide to palladium catalyst in step a is (1-5):1, preferably 2: 1.
In a specific embodiment, the base in step a is one or a combination of diethylamine, triethylamine and diisopropylethylamine, and triethylamine is preferred.
In a specific embodiment, the reaction temperature in step a is 55 ℃ and the reaction time is 24 h.
In a specific embodiment, the solvent in step b is one or a combination of methanol, ethanol, isopropanol and water, and methanol is preferred.
In a specific embodiment, the base in step b is one or a combination of potassium carbonate, sodium carbonate, potassium phosphate, sodium hydroxide and tetrabutylammonium fluoride, and potassium carbonate is preferred.
In a specific embodiment, the reaction temperature in step b is 20-30 ℃ and the reaction time is 1-3 h.
In a specific embodiment, the organic solvent in step c is one or a combination of several of toluene, 1, 4-dioxane, tetrahydrofuran, acetonitrile, and N, N-dimethylformamide, and preferably 1, 4-dioxane.
In a particular embodiment, the catalyst in step c is generated in situ in the reaction from a divalent nickel salt and a phosphine ligand.
In a specific embodiment, the divalent nickel salt in step c is Ni (OAc) 2 、Ni(acac) 2 、Ni(OTf) 2 、NiBr 2 、NiCl 2 Preferably Ni (acac) 2 。
In a particular embodiment, the molar ratio of the divalent nickel salt to 4-ethynyl-2-fluorobiphenyl (6) in step c is 1 (20-50), preferably 1: 20.
In a specific embodiment, the phosphine ligand in step c is one or more of 1, 2-bis (dicyclohexylphosphino) ethane (dcpe), 1, 3-bis (dicyclohexylphosphino) propane (dcpp), 1, 2-bis (diphenylphosphino) ethane (dppe) in combination, preferably 1, 2-bis (dicyclohexylphosphino) ethane (dcpe).
In a particular embodiment, the molar ratio of phosphine ligand to divalent nickel salt in step c is (1-3):1, preferably 1.2: 1.
In a specific embodiment, the acid anhydride in step c is one or a combination of acetic anhydride, trifluoroacetic anhydride and benzoic anhydride, preferably acetic anhydride.
In a particular embodiment, the molar ratio of the anhydride to 4-ethynyl-2-fluorobiphenyl (6) in step c is 1:
(3-10), preferably 1: 3.33.
In a particular embodiment, the molar ratio of formic acid, triethylamine and 4-ethynyl-2-fluorobiphenyl (6) in step c is (4-8): 1-3):1, preferably 6:2: 1.
In a specific embodiment, the reaction temperature in step c is 60-90 ℃ and the reaction time is 24-36 h.
In a specific embodiment, the catalyst in step d is generated in situ in the reaction from a divalent nickel salt and a chiral phosphine ligand. Experiments prove that the complex formed by the chiral ligand and the divalent nickel has the highest catalytic activity and higher enantioselectivity.
In a specific embodiment, the chiral phosphine ligand in step d is a chiral alkyl diphosphine ligand, which is one or more of (R, R) -BenzP, (R, R) -DuanPhos, (R, R) -Me-BPE, preferably (R, R) -BenzP.
In a particular embodiment, the molar ratio of the chiral phosphine ligand to the divalent nickel salt in step d is (1-3: 1, preferably 1.2: 1.
In a specific embodiment, the types and material molar ratios of the solvent, the nickel salt, the anhydride, the formic acid and the triethylamine in the step d, the reaction temperature and the reaction time, and the experimental steps are the same as those in the step c.
In a specific embodiment, the catalyst in step e is generated in situ in the reaction from a divalent nickel salt and a chiral phosphine ligand. Experiments prove that the complex formed by the chiral ligand and the divalent nickel has the highest catalytic activity and higher enantioselectivity.
In a specific embodiment, the chiral phosphine ligand in step e is chiral alkyl diphosphine ligand, which is one or more of (S, S) -BenzP, (S, S) -DuanPhos and (S, S) -Me-BPE, preferably (S, S) -BenzP.
In a particular embodiment, the molar ratio of chiral phosphine ligand to divalent nickel salt in step e is (1-3: 1, preferably 1.2: 1.
In a specific embodiment, the types and material molar ratios of the solvent, the nickel salt, the anhydride, the formic acid and the triethylamine in the step e, the reaction temperature and the reaction time, and the experimental steps are the same as those in the step c.
The reaction formulae of steps a and b are as follows:
Figure BDA0003635708750000061
the reaction formula of step c is as follows:
Figure BDA0003635708750000062
the reaction formula of step d is as follows:
Figure BDA0003635708750000063
the reaction formula of step e is as follows:
Figure BDA0003635708750000064
the invention will be further explained and illustrated with reference to specific examples.
Example 1:preparation of 4-ethynyl-2-fluorobiphenyl (6)
Pd (PPh) was added to a 10mL Schlenk reaction tube under nitrogen protection 3 ) 2 Cl 2 (70mg,0.1mmol), cuprous iodide (38mg,0.2mmol) and tetrahydrofuran (5mL) were added to a reaction tube under stirring 4-bromo-2-fluorobiphenyl (4) (1.19g,5mmol), trimethylsilylacetylene (5) (614mg,6.25mmol), triethylamine (784mg,7.75mmol) and the reaction was sealed and allowed to react at 55 ℃ for 24 hours. After the reaction was stopped, most of the solvent was evaporated by a rotary evaporator, the residue was dissolved in methanol, and potassium carbonate (1.38g,10mmol) was added to react at room temperature for 2 hours. After the reaction is finished, evaporating most of the solvent by using a rotary evaporator, dissolving the crude product by using a small amount of solvent, transferring the crude product to a silica gel chromatographic column, and eluting the crude product by using petroleum ether to obtain pure white solid 4-ethynyl-2-fluorobiphenyl (6) with the yield of 93 percent. The nuclear magnetic data are as follows:
1 H NMR(400MHz,CDCl 3 ):δ7.52(m,2H),7.43(m,2H),7.35(m,3H),7.27(m,1H),3.12(s,1H).
13 C NMR(101MHz,CDCl 3 ):δ159.26(d,J C-F ＝248.8Hz),135.10(d,J C-F ＝1.1Hz),130.77(d,J C-F ＝4.2Hz),130.05(d,J C-F ＝13.6Hz),129.04(d,J C-F ＝3.1Hz),128.66,128.39(d,J C-F ＝3.5Hz),128.20,122.83(d,J C-F ＝9.7Hz),119.83(d,J C-F ＝24.9Hz),82.43(d,J C-F ＝3.0Hz),78.64.
example 2: preparation of racemic flurbiprofen (1)
Under nitrogen protection, a 10mL Schlenk reaction tube was charged with Ni (acac) 2 (2.6mg,0.01mmol), 1, 2-bis (dicyclohexylphosphinyl) ethane (dcpe,5.1mg,0.012mmol) and 1, 4-dioxane (0.6mL), stirred for 10 min, and added 4-ethynyl-2-fluorobiphenyl (6, 39mg,0.2mmol), acetic anhydride (6.1mg,0.06mmol), formic acid (55.2mg,1.2mmol) and triethylamine (40.5mg,0.4 mmol). The reaction tube was sealed and heated in a 70 ℃ oil bath for 24 hours. After the reaction was stopped, cooling was performed, 1M NaOH (3mL) was added, stirring was performed for 10 minutes, the mixture was transferred to a separatory funnel, the aqueous phase was washed with 10mL of ether 3 times, 1M hydrochloric acid was added to adjust the pH to acidity, the product was extracted with 10mL of dichloromethane 3 times, the organic phases were combined, dried over anhydrous sodium sulfate, concentrated in vacuo, and purified by column chromatography to obtain 45mg of flurbiprofen as a white solid with a yield of 93%. The nuclear magnetic data are as follows:
1 H NMR(400MHz,CDCl 3 ):δ11.33(brs,1H),7.54-7.52(m,2H),7.46-7.35(m,4H),7.19-7.13(m,2H),3.79(q,J＝7.2Hz,1H),1.56(d,J＝7.2Hz,3H).
13 C NMR(101MHz,CDCl 3 ):δ180.49,159.81(d,J C-F ＝248.5Hz),141.02(d,J C-F ＝7.7Hz),135.53,131.03(d,J C-F ＝4.0Hz),129.09(d,J C-F ＝2.9Hz),128.59,128.30(d,J C-F ＝13.5Hz),127.86,123.83(d,J C-F ＝3.4Hz),115.52(d,J C-F ＝23.8Hz),44.99,18.12.
example 3: preparation of (R) - (-) -flurbiprofen (2)
Under nitrogen protection, a 10mL Schlenk reaction tube was charged with Ni (acac) 2 (2.6mg,0.01mmol), (R, R) -BenzP (3.4mg,0.012mmol) and 1, 4-dioxane (0.6mL), stirred for 10 min, added with 4-ethynyl-2-fluorobiphenyl (6, 39mg,0.2mmol), acetic anhydride (6.1mg,0.06mmol), formic acid (55.2mg,1.2mmol) and triethylamine (40.5mg,0.4 mmol). The reaction tube was sealed and heated in a 70 ℃ oil bath for 24 hours. After the reaction had ceased, it was cooled, 1M NaOH (3mL) was added, stirred for 10 min, transferred to a separatory funnel, the aqueous phase was washed 3 times with 10mL of diethyl ether, the pH was adjusted to acidity by the addition of 1M hydrochloric acid, the product was extracted 3 times with 10mL of dichloromethane, the organic phases were combined, dried over anhydrous sodium sulfate, concentrated in vacuo and the residue recrystallized from the appropriate amount of petroleum ether. Filtering and collecting the product, and drying in vacuum to obtain white (R) - (-) -flurbiprofen(2) Needle-shaped crystal with yield of 90%, melting point of 102 ℃ and specific optical rotation [ alpha ] of 103 DEG C] D 25 -40 ° (c ═ 1, methanol), ee by HPLC 94%, determined by the following method: xylonite chiral column AD-H, n-hexane/isopropanol 97/3,0.8mL/min, retention time t major ＝19.6min,t minor ＝31.8min。
Example 4: preparation of (S) - (+) -flurbiprofen (3)
Under the protection of nitrogen, Ni (acac) was added to a 10mL Schlenk reaction tube 2 (2.6mg,0.01mmol), (S, S) -BenzP (3.4mg,0.012mmol) and 1, 4-dioxane (0.6mL), stirred for 10 min, added with 4-ethynyl-2-fluorobiphenyl (6, 39mg,0.2mmol), acetic anhydride (6.1mg,0.06mmol), formic acid (55.2mg,1.2mmol) and triethylamine (40.5mg,0.4 mmol). The reaction tube was sealed and heated in a 70 ℃ oil bath for 24 hours. After the reaction had ceased, it was cooled, 1M NaOH (3mL) was added, stirring for 10 min, and the mixture was transferred to a separatory funnel, the aqueous phase was washed 3 times with 10mL diethyl ether, 1M hydrochloric acid was added to adjust the pH to acidity, the product was extracted 3 times with 10mL dichloromethane, the organic phases were combined, dried over anhydrous sodium sulfate, concentrated in vacuo, and the residue was recrystallized from the appropriate amount of petroleum ether. The product is collected by filtration and dried in vacuum to obtain white needle-shaped crystals of (S) - (+) -flurbiprofen (3), the yield is 91 percent, the melting point is 101 and 102 ℃, and the specific optical rotation alpha is] D 25 +41 ° (c-1, methanol), ee value by HPLC 93%, determined by: xylonite chiral column AD-H, n-hexane/isopropanol 97/3,0.8mL/min, retention time t minor ＝19.0min,t major ＝31.1min。
The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims (10)

1. A catalyst, characterized by: comprises a complex generated in situ by a divalent nickel salt and a phosphine ligand;
preferably, the molar ratio of the phosphine ligand to the divalent nickel salt is (1-3): 1;
more preferably, the molar ratio of the phosphine ligand to divalent nickel salt is 1.2: 1.
2. The catalyst of claim 1, wherein: the divalent nickel salt is Ni (OAc) 2 、Ni(acac) 2 、Ni(OTf) 2 、NiBr 2 And NiCl 2 One or a combination of several of them;
preferably, the divalent nickel salt is Ni (acac) 2 。
3. The catalyst of claim 1, wherein: the phosphine ligands include achiral phosphine ligands and chiral phosphine ligands.
4. The catalyst of claim 3, wherein: the achiral phosphine ligand is one or a combination of more of 1, 2-bis (dicyclohexyl phosphonium) ethane (dcpe), 1, 3-bis (dicyclohexyl phosphonium) propane (dcpp) and 1, 2-bis (diphenyl phosphine) ethane (dppe);
preferably, the achiral phosphine ligand is 1, 2-bis (dicyclohexylphosphino) ethane (dcpe).
5. The catalyst of claim 3, wherein: the chiral phosphine ligand comprises an R-configuration chiral phosphine ligand;
preferably, the R configuration chiral phosphine ligand is one or a combination of (R, R) -BenzP, (R, R) -DuanPhos and (R, R) -Me-BPE;
more preferably, the R-configured chiral phosphine ligand is (R, R) -BenzP.
6. The catalyst of claim 5, wherein: the molar ratio of the R configuration chiral phosphine ligand to the divalent nickel salt is (1-3) to 1;
preferably, the molar ratio of the R configuration chiral phosphine ligand to the divalent nickel salt is 1.2: 1.
7. The catalyst of claim 3, wherein: the chiral phosphine ligand comprises an S-configuration chiral phosphine ligand;
preferably, the S configuration chiral phosphine ligand is one or a combination of (S, S) -BenzP, (S, S) -DuanPhos and (S, S) -Me-BPE;
more preferably, the S-configuration chiral phosphine ligand is (S, S) -BenzP.
8. The catalyst of claim 7, wherein: the molar ratio of the S-configuration chiral phosphine ligand to the divalent nickel salt is (1-3) to 1;
preferably, the molar ratio of the S-configuration chiral phosphine ligand to divalent nickel salt is 1.2: 1.
9. The catalyst of claim 1, wherein: the modified acrylic acid further comprises acid anhydride, wherein the acid anhydride is one or a combination of more of acetic anhydride, trifluoroacetic anhydride and benzoic anhydride;
preferably, the anhydride is acetic anhydride.
10. Use of a catalyst according to any one of claims 1 to 9 in the preparation of flurbiprofen;
preferably, the flurbiprofen comprises racemic flurbiprofen, optically pure levoflurbiprofen and optically pure dextro-flurbiprofen.
CN202210501832.6A 2021-01-26 2021-01-26 Catalyst and application thereof Active CN114887666B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210501832.6A CN114887666B (en) 2021-01-26 2021-01-26 Catalyst and application thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210501832.6A CN114887666B (en) 2021-01-26 2021-01-26 Catalyst and application thereof
CN202110104844.0A CN112778115B (en) 2021-01-26 2021-01-26 Preparation method of flurbiprofen

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202110104844.0A Division CN112778115B (en) 2021-01-26 2021-01-26 Preparation method of flurbiprofen

Publications (2)

Publication Number Publication Date
CN114887666A true CN114887666A (en) 2022-08-12
CN114887666B CN114887666B (en) 2023-12-22

Family

ID=75757291

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210501832.6A Active CN114887666B (en) 2021-01-26 2021-01-26 Catalyst and application thereof
CN202110104844.0A Active CN112778115B (en) 2021-01-26 2021-01-26 Preparation method of flurbiprofen

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110104844.0A Active CN112778115B (en) 2021-01-26 2021-01-26 Preparation method of flurbiprofen

Country Status (1)

Country Link
CN (2) CN114887666B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101973869A (en) * 2010-11-02 2011-02-16 中国科学技术大学 Method for synthesis of flurbiprofen
CN103012144A (en) * 2012-12-26 2013-04-03 哈药集团技术中心 Preparation method of flurbiprofen axetil
CN105566021A (en) * 2015-12-30 2016-05-11 中国科学技术大学 Preparation method of alpha, beta-unsaturated carboxylic acid compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101633615B (en) * 2008-07-22 2013-06-12 中国科学院成都有机化学有限公司 Method for synthesizing acrylic acid from acetylene carbonyl
CN105601504B (en) * 2016-03-30 2018-01-09 郑州西格玛化工有限公司 A kind of preparation method of 2 (xenyl of 2 fluorine 4) propionic acid
CN106496015B (en) * 2016-11-01 2019-07-26 河北美星化工有限公司 A kind of preparation method of Flurbiprofen
CN106496016B (en) * 2016-11-01 2019-07-26 河北美星化工有限公司 A kind of synthetic method of Flurbiprofen
CN109305911A (en) * 2017-07-28 2019-02-05 郑建鸿 The preparation method of polysubstituted acyclic compound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101973869A (en) * 2010-11-02 2011-02-16 中国科学技术大学 Method for synthesis of flurbiprofen
CN103012144A (en) * 2012-12-26 2013-04-03 哈药集团技术中心 Preparation method of flurbiprofen axetil
CN105566021A (en) * 2015-12-30 2016-05-11 中国科学技术大学 Preparation method of alpha, beta-unsaturated carboxylic acid compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ERIC LABBE等: "Ligand-directed reaction products in the nickel-catalyzed electrochemical carboxylation of terminal alkynes", 《JOURNAL OF ORGANOMETAILIC CHEMISTRY》, vol. 353, pages 51 *
FU-SHE HAN等: "Transition-metal-catalyzed Suzuki–Miyaura cross-coupling reactions: a remarkable advance from palladium to nickel catalysts", 《CHEM SOC REV》, vol. 42, pages 5270 *
HONGYU ZHONG等: "Cobalt-Catalyzed Asymmetric Hydrogenation of α, β-Unsaturated Carboxylic Acids by Homolytic H2 Cleavage", 《JACS》, vol. 142, pages 5272 - 5281 *
崔龙 等: "膦配体对乙炔羰化制丙烯酸催化剂NiBr2-CuBr2性能的影响", 《无机化学学报》, vol. 30, no. 7, pages 1600 - 1608 *

Also Published As

Publication number Publication date
CN114887666B (en) 2023-12-22
CN112778115B (en) 2022-08-09
CN112778115A (en) 2021-05-11

Similar Documents

Publication Publication Date Title
Ding et al. Highly efficient and practical optical resolution of 2‐amino‐2′‐hydroxy‐1, 1′‐binaphthyl by molecular complexation with N‐benzylcinchonidium chloride: a direct transformation to binaphthyl amino phosphine
Hayashi et al. Asymmetric synthesis catalyzed by chiral ferrocenylphosphine-transition-metal complexes. 8. Palladium-catalyzed asymmetric allylic amination
JP3681418B2 (en) New bisphosphines for asymmetric hydrogenation catalysts
JP2009073841A (en) Asymmetric synthesis of pregabalin
Rachwalski et al. Aziridine ring-containing chiral ligands as highly efficient catalysts in asymmetric synthesis
CN110128341B (en) Chiral 2, 2' -bipyridyl ligand, preparation method thereof and application thereof in preparation of chiral cyclopropane derivative
US5198561A (en) Ruthenium-BINAP asymmetric hydrogenation catalyst
Widhalm et al. Chiral ferrocene derivatives containing a 2, 2′-bridged binaphthyl moiety
CN112778115B (en) Preparation method of flurbiprofen
CN112479982B (en) Preparation method of chiral indole-2,3-octatomic carbocyclic compound
CA2097423A1 (en) Method for preparing .alpha.-arylpropionic acids
CN109575060B (en) Synthesis of spiro bisboron catalyst and application of spiro bisboron catalyst in hydrogenation reaction
JP3020128B2 (en) Method for producing optically active carboxylic acid
EP2139839B1 (en) A method for preparation of 6-ý3-(1-adamantyl)-4-methoxyphenyl¨-2-naphtoic acid
JP2005023055A (en) New optically active amine
WO2001036359A1 (en) Optically active fluorinated binaphthol derivative
CN111943874A (en) Aryl naproxen derivative high-valence iodine compound and preparation method and application thereof
CN114591228B (en) Chiral styryl pyridyl sulfoxide and synthesis method thereof
CN114262308B (en) 2-methylene-2, 3-dihydrothiazole compound and synthetic method and application thereof
JPH0641444B2 (en) Method for producing optically active threonine
CN112028800B (en) Cysteine derivative and synthesis method thereof
JP4373933B2 (en) (1S, 2S)-or (1R, 2R) -cis-1-arylphosphorane-2-carboxylic acid / borane complex and method for producing the same
JPS60112735A (en) Manufacture of optically active alpha-arylalkanoic acids andprecursor therefor
CN116675629A (en) Chiral dicarboxylic acid tetradentate binuclear rhodium catalyst based on natural amino acid, synthesis method and application thereof
JPH03106845A (en) Preparation of optionally active 2-aryl-propionic acids

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant